Table 1.
Expression and role of CBS in various cancers.
| Colorectal cancer | Ovarian cancer | Breast cancer | Urothelial cell carcinoma of bladder | Lung adeno-carcinoma | Renal cancers | Oral and esophageal carcinoma | Extrahepatic cholangio-carcinoma | Gallbladder adenocarcinoma | Gastric cancer | Multiple myeloma | Liver cancer | Glioma, glioblastoma | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CBS protein expression in clinical tumor tissue relative to surrounding normal | Higher | Higher | Higher | Higher | Higher | Higher | Higher | Higher | Higher | Higher | Not yet assessed | Lower | Lower |
| Correlation of CBS protein expression in clinical tumor specimen with disease stage | Correlation confirmed both in terms of colon cancer stage and also in terms of progression from polyp formation to colon adenocarcinoma formation | Correlation confirmed | Correlation confirmed for basal-like cancer | Not yet assessed | Not yet assessed | Inconclusive data | Not yet assessed | Correlation confirmed | Not yet assessed | Not yet assessed | Not yet assessed | Not yet assessed | Not yet assessed |
| CBS mRNA expression in clinical tumor tissue relative to surrounding normal | Higher | Higher | Higher | Not yet assessed | Higher | Not yet assessed | Not yet assessed | Not yet assessed | Not yet assessed | Higher | Higher | Lower | Lower |
| Correlation of CBS mRNA expression in clinical tumor tissues with clinical prognosis | Higher CBS mRNA is associated with worse clinical outcomes in several (but not all) published analyses | Higher CBS mRNA is associated with worse clinical outcomes | Higher CBS mRNA is associated with worse clinical outcomes | Higher CBS mRNA tends to be associated with better clinical outcomes. | Higher CBS mRNA is associated with worse clinical outcomes. | Higher CBS mRNA is associated with worse clinical outcomes (especially in renal clear cell carcinoma) | Not yet assessed | Higher CBS mRNA is associated with worse clinical outcomes. | Not yet assessed | Higher CBS mRNA is associated with worse clinical outcomes and poorer chemotherapy responses | Not yet assessed | Higher CBS mRNA is associated with better clinical outcomes. | Higher CBS mRNA tends to be associated with better clinical outcomes. |
| Expression in human cancer cell lines | High expression: HCT116, LoVo, HT-29, DLD-1, SW480, CTC-MCC-41 | High expression: OV202, SKOV3, A2780, A2780/CP-70, CP20, OV90, OVCAR3, OVCAR4, OVCAR5, OVCA429 |
High expression: MDA-MB-231 MDA-MB-435S, MDA-MB-468, MCF-7, Hs578T, Cal51, HCC1143 | High expression: RT4, SW780, 5637, T24, EJ, UM-UC-3 | High expression in A549, H522, H1944, 95D, Calu-6 | Average expression: Caki-1, 786-O, 769-P is comparable to non-transformed cell controls | Variable expression ranging from non-detectable to high: KYSE510, KYSE150, KYSE140, Eca109, EC9706, TE-13, KYSE70, KYSE450 | Not yet assessed | Not yet assessed | Average expression: BGC-823, SGC-7901 | Average/low expression: U266 | Relatively high CBS expression: HepG2, SMMC-7721, BEL-7402, BEL-7404 | Relatively low CBS expression: U87-MG, hGBM 23, hGBM 124, hGBM 3691, BT142, TS603, NCH1681 |
| Effect of CBS silencing in human cancer cell lines in vitro | Inhibition of tumor growth, potentiation of the effect of chemotherapy | Inhibition of tumor growth, potentiation of the effect of chemotherapy | Inhibition of tumor growth, potentiation of the effect of immune cell mediated tumor killing | Not yet assessed | Inhibition of tumor growth, potentiation of the effect of chemotherapy | Not yet assessed | Inhibition of tumor growth | Not yet assessed | Not yet assessed | Not yet assessed | Not yet assessed | Variable effects: either pro- or antiproliferative and either cytotoxic or cytoprotective actions in various hepatoma cell lines | Stimulation of tumor growth |
| Effect of CBS silencing in human cancer cell lines on tumor growth in tumor-bearing mice | Inhibition of tumor growth | Inhibition of tumor growth, potentiation of the effect of chemotherapy | Not yet assessed | Not yet assessed | Not yet assessed | Not yet assessed | Not yet assessed | Not yet assessed | Not yet assessed | Not yet assessed | Not yet assessed | Enhancement of tumor growth | Enhancement of tumor growth |